Shionogi & Co., Ltd. raised its full-year forecast for fiscal 2026. It emphasized growth through overseas expansion and a new-drug-focused strategy, targeting revenue of ¥720 billion and operating profit of ¥230 billion.
At its briefing on second-quarter results for fiscal 2026, Shionogi & Co., Ltd. raised its full-year forecast and indicated that achieving revenue of ¥720 billion and operating profit of ¥230 billion would establish a growth trajectory from the next fiscal year onward. The company said second-quarter performance remained solid across multiple domestic and overseas areas.
In Japan, growth in products for quality-of-life disease areas, including the insomnia treatment QUVIVIQ, the ALS treatment Radicut and products related to Torii Pharmaceutical, was judged to have strengthened a stable earnings base less susceptible to infectious-disease outbreaks. Second-quarter revenue was ¥350.4 billion, operating profit was ¥115.2 billion, interim profit before tax was ¥107.3 billion, and interim profit attributable to owners of the parent was ¥119.5 billion.
In China, the company decided to sell its generic-drug business to 高跡医薬社 in response to changes in the business environment. It explained that revenue had fallen by approximately half over the three years from 2022 and that the business had incurred losses of ¥2.5 billion to ¥3.0 billion, emphasizing the importance of shifting to a business structure centered on new drugs.
The acquisition of Intrabio was valued at ¥315.6 billion, and the company indicated a policy of positioning rare diseases as a new growth area. It expects the business to become a growth engine in Europe and the United States, and expressed expectations for the use of new-drug-related technologies such as アクニューサ and faster product delivery in those markets. It also mentioned obtaining approval in the United States for an additional A-T indication.